Accumulating data show the efficacy of adjuvant EGFR–tyrosine kinase inhibitors (EGFR–TKIs) for treating patients with resected EGFR-mutant NSCLC [9–11]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.